{"title":"Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature.","authors":"Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada","doi":"10.1093/skinhd/vzaf011","DOIUrl":null,"url":null,"abstract":"<p><p>Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8<sup>+</sup> T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"151-153"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068473/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/skinhd/vzaf011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8+ T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.